Mostrar el registro sencillo del ítem

dc.contributorUniversitat Ramon Llull. IQS
dc.contributor.authorMontagut, Ana Maria
dc.contributor.authorArmengol, Marc
dc.contributor.authorGorjón de Pablo, Gema
dc.contributor.authorEstrada Tejedor, Roger
dc.contributor.authorBorrell Bilbao, José Ignacio
dc.contributor.authorRoué, Gaël
dc.date.accessioned2024-11-01T14:44:01Z
dc.date.available2024-11-01T14:44:01Z
dc.date.issued2022-12
dc.identifier.issn1096-3634ca
dc.identifier.urihttp://hdl.handle.net/20.500.14342/4513
dc.description.abstractAs a post-translational modification that has pivotal roles in protein degradation, ubiquitination ensures that intracellular proteins act in a precise spatial and temporal manner to regulate diversified cellular processes. Perturbation of the ubiquitin system contributes directly to the onset and progression of a wide variety of diseases, including various subtypes of cancer. This highly regulated system has been for years an active research area for drug discovery that is exemplified by several approved drugs. In this review, we will provide an update of the main breakthrough scientific discoveries that have been leading the clinical development of ubiquitin-targeting therapies in the last decade, with a special focus on E1 and E3 modulators. We will further discuss the unique challenges of identifying new potential therapeutic targets within this ubiquitous and highly complex machinery, based on available crystallographic structures, and explore chemical approaches by which these challenges might be met.ca
dc.format.extentp.17ca
dc.language.isoengca
dc.publisherElsevierca
dc.relation.ispartofSeminars in Cell & Developmental Biology 2022, 132, 213-229ca
dc.rights© L'autor/aca
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.otherUbiquitin ligaseca
dc.subject.otherDeubiquitinaseca
dc.subject.otherCancerca
dc.subject.otherStructure-based drug designca
dc.subject.otherPreclinical screeningca
dc.subject.otherClinical trialca
dc.subject.otherUbiqüitinaca
dc.subject.otherCàncerca
dc.subject.otherAssaigs clínicsca
dc.titleRecent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancerca
dc.typeinfo:eu-repo/semantics/articleca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc616ca
dc.identifier.doihttps://doi.org/10.1016/j.semcdb.2022.02.007ca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca


Ficheros en el ítem

 

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

© L'autor/a
Excepto si se señala otra cosa, la licencia del ítem se describe como http://creativecommons.org/licenses/by/4.0/
Compartir en TwitterCompartir en LinkedinCompartir en FacebookCompartir en TelegramCompartir en WhatsappImprimir